Back to Journals » International Journal of Nanomedicine » Volume 7

Indomethacin-loaded lipid-core nanocapsules reduce the damage triggered by Aβ1-42 in Alzheimer’s disease models

Authors Bernardi A, Frozza, Meneghetti, Hoppe, Oliveira Battastini AM, Pohlmann, Guterres S, Salbego

Received 25 June 2012

Accepted for publication 20 July 2012

Published 13 September 2012 Volume 2012:7 Pages 4927—4942


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Andressa Bernardi,1,* Rudimar L Frozza,2,* André Meneghetti,2 Juliana B Hoppe,2 Ana Maria O Battastini,2 Adriana R Pohlmann,1,3 Sílvia S Guterres,3 Christianne G Salbego2

1Programa de Pós-Graduação em Ciências Farmacêuticas, 2Instituto de Ciências Básicas da Saúde, 3Instituto de Química, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

*These authors contributed equally to this work

Abstract: Neuroinflammation, characterized by the accumulation of activated microglia and reactive astrocytes, is believed to modulate the development and/or progression of Alzheimer’s disease (AD). Epidemiological studies suggesting that nonsteroidal anti-inflammatory drugs decrease the risk of developing AD have encouraged further studies elucidating the role of inflammation in AD. Nanoparticles have become an important focus of neurotherapeutic research because they are an especially effective form of drug delivery. Here, we investigate the potential protective effect of indomethacin-loaded lipid-core nanocapsules (IndOH-LNCs) against cell damage and neuroinflammation induced by amyloid beta (Aβ)1-42 in AD models. Our results show that IndOH-LNCs attenuated Aβ-induced cell death and were able to block the neuroinflammation triggered by Aβ1-42 in organotypic hippocampal cultures. Additionally, IndOH-LNC treatment was able to increase interleukin-10 release and decrease glial activation and c-jun N-terminal kinase phosphorylation. As a model of Aβ-induced neurotoxicity in vivo, animals received a single intracerebroventricular injection of Aβ1-42 (1 nmol/site), and 1 day after Aβ1-42 infusion, they were administered either free IndOH or IndOH-LNCs (1 mg/kg, intraperitoneally) for 14 days. Only the treatment with IndOH-LNCs significantly attenuated the impairment of this behavior triggered by intracerebroventricular injection of Aβ1-42. Further, treatment with IndOH-LNCs was able to block the decreased synaptophysin levels induced by Aβ1-42 and suppress glial and microglial activation. These findings might be explained by the increase of IndOH concentration in brain tissue attained using drug-loaded lipid-core NCs. All these findings support the idea that blockage of neuroinflammation triggered by Aβ is involved in the neuroprotective effects of IndOH-LNCs. These data provide strong evidence that IndOH-LNC treatment may represent a promising approach for treating AD.

Keywords: Alzheimer’s disease, neuroinflammation, lipid-core nanocapsules, drug delivery, indomethacin, neuroprotection

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]